Product Name : BPC 157
CAS : 137525-51-0
MF : C62H98N16O22 
MW : 1419.53552 
Purity : 99%
Grade : Pharmaceutical Grade
Appearance : White Crystalline Powder
Specification: 5mg/vial, 10vial/box
Appearance: White Lyophilized Powder
Place of Origin: China


BPC 157 has a strong anti-inflammatory activity in both acute and chronic inflammation models. In fact, preliminary results in clinical trials suggest that BPC 157 may become an important therapeutic tool for the treatment of inflammatory bowel disease. BPC 157 was shown to accelerate wound healing and to have a marked angiogenic effect. In addition, it significantly facilitates the healing of bone fracture in rats. This peptide also exhibits an osteogenic effect significantly improving the healing of segmental bone defect. BPC 157 accelerates the healing of transected rat Achilles tendon and transected rat quadriceps muscle. 

PT 141 is a synthetic amino acid protein discovered during clinical trials using the Melanotan 2 for sunless tanning, photo-protection results from melanotans. The melanocortin system targets receptors associated with desire through the melanocyte stimulating hormone paths that cross the blood-brain-barrier. Potentially the powerful sex-drug results feeling an aphrodisiac experience amplifying arousal pt 141 reviews have shown the ability to increase libido effects of both men and women

Potential benefits

PT 141 in Men:

• effective in a broad range of patients, including those with severe ED and those non-responsive to sildenafil
• efficacy in "at-home" studies is comparable to PDE-5 inhibitors
• up to 50% of ED patients were restored to a normal level of function
• co-administration with sildenafil shows superior efficacy
• side effects include facial flushing, nausea, aftertaste and post-nasal drip

PT 141 in Women:

Palatin conducted a Phase 2A study in 18 premenopausal women with a diagnosis of female sexual
dysfunction (FSD). Patients reported a significant increase in sexual desire and in genital arousal after
receiving PT 141, compared to
placebo. Additionally, there was a correlation between sexual desire and genital arousal in patients receiving
PT 141, an observation that further reinforces the potential importance of these reports.